• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Interdisciplinary symposium targets PI3K pathway

PI3K Panelists

On October 4, the Center Scientific Council (CSC) hosted a symposium titled “Targeting the PI3K Pathway for Cancer Therapy,” the first of a quarterly series of workshops on emerging avenues of interdisciplinary research. Chaired by Lewis Cantley, PhD (BIDMC), the event featured presentations on PI3K/PTEN in breast cancer, identifying PI3K-activated tumors, mouse models for PI3K-driven tumors, and clinical trials of PI3K inhibitors (see agenda and videos below).

“Because the PI3K pathway is perturbed in many different cancers,” says Sarah Weiler, PhD, the DF/HCC deputy associate director for program coordination, “the Executive Committee and CSC recognized an opportunity for collaboration and cross-fertilization among disease programs and across disciplines.” Topics under consideration for future workshops include: “Vitamin D and Cancer Prevention” and “Obesity and Nutrition in Cancer.”

Download the agenda

Overview of the PI3K pathway

Lewis Cantley, PhD

PI3K/PTEN in Breast Cancer

Ramon Parsons, MD, PhD
Breast Cancer Research, Institute for Cancer Genetics, Columbia University

Identifying tumors with activated PI3K Pathway

Ralph Weissleder, MD, PhD MGH, Center for Molecular Imaging Research

 

Pasi Janne, MD, PhD, DFCI, Dept. of Adult Oncology

 

Todd Golub, MD, DFCI, Dept. of Pediatric Oncology

 

Alexander Miron, PhD DFCI, Dept. of Cancer Biology

Mouse models for PI3K driven tumors

Thomas Roberts, PhD DFCI, Dept. of Cancer Biology

 

Jeffrey A. Engelman, MD, PhD MGH, Dept. of Hematology/Oncology

Clinical Trials for PI3K inhibitors

Massimo Loda, MD DFCI, Pathology

Download Windows Media Player

Video available in Windows Media Player format.  If you click on the video links above and nothing happens, please download a copy of Windows Media Player for free.